- InterView
- 'Viatris will lead market with innovation and leadership'
- by Whang, byung-woo Jun 10, 2025 06:04am
- “Viatris Korea is pursuing growth through two pillars: a core brand-focused business and new pipelines. Based on the pillars, we expect to secure growth momentum once again on a global scale.” Viatris Korea is working to strengthen its position in the domestic market by introducing a global innovative pipeline and driving continuous growth
- InterView
- "Livtencity offers new CMV trt for transplant patients"
- by Whang, byung-woo Jun 4, 2025 06:19am
- "Cytomegalovirus (CMV) infection is worse than a simple viral infection in patients with solid organ transplant (SOT), but existing treatments have limitations. Reimbursement of new medicines is meaningful in terms of extending treatment options." Livtencity (maribavir), which can be prescribed to post-transplant patients who have had limited
- InterView
- ‘SGLT2i+TZD promising for diabetics with fatty liver risk’
- by Kim, Jin-Gu May 26, 2025 05:55am
- A large-scale epidemiological study conducted on a Korean population has found that metabolic dysfunction-associated steatotic liver disease (MASLD), which commonly accompanies diabetes, increases the risk of cardiovascular disease and mortality. MASLD is not merely a liver disease but a cause that exacerbates overall metabolic disorders, mak
- InterView
- Hemlibra shows long-term efficacy and safety in hemophilia
- by Kim, Jin-Gu May 16, 2025 06:19am
- &160;“The hemophilia patients’ only desire is to lead a normal life like everyone else. Hemlibra (emicizumab) has been found to be effective in preventing bleeding and safe in long-term follow-up studies. Moreover, it demonstrates clear bleeding prevention effects even during high-intensity exercise, significantly helping patients lead no
- InterView
- "High hopes for reimbursed Ilaris…a new treatment option"
- by Whang, byung-woo Feb 5, 2025 05:52am
- The Hereditary Periodic Fever (HPF) syndromes cause not just fever and pain but affect various aspects, such as patient's growth and development, psychological elements. The reimbursement coverage of a new treatment in nine years has increased patient satisfaction." Clinical practices have high hopes for changes to the treatment setting as Il
- InterView
- Approval called for drug switching in atopic dermatitis
- by Whang, byung-woo Jan 24, 2025 05:51am
- Atopic dermatitis treatment settings are changing quickly. New treatment options are available as new drugs with fewer side effects and superior treatment effectiveness than existing therapies emerge. There is a growing interest in how atopic dermatitis can be treated rather than just treating it, as changes have been brought to the treatment
- InterView
- "Reimb granted to drug switching between JAK inhibitors"
- by Son, Hyung Min Dec 26, 2024 05:50am
- "Until now, drug switching between JAK inhibitors has not been reimbursed, so there have been unmet patient needs for rheumatoid arthritis patients who do not benefit from conventional biological agents. As reimbursement for drug switching will be granted starting in December, patients will be less burdened by switching from biological agent
- InterView
- ‘New start at a law firm…will become a trusted expert’
- by Kim, Jin-Gu Dec 13, 2024 05:52am
- The role of law firms has greatly expanded in the pharmaceutical bio and healthcare sectors recently. Whereas law firms used to provide piecemeal legal services in the past, law firms have now been providing comprehensive services over a long period of time, covering the whole course of a drug’s journey from pre-approval to reimbursement.
- InterView
- ‘3 IBD treatment trends…early treatment is the first’
- by Kim, Jin-Gu Dec 2, 2024 05:49am
- The treatment method for a single disease can continue to change at a very fast pace. This is true for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. In recent years, a variety of drugs have been developed to treat these diseases, and the treatment trend is changing as more research is conducted. Dr. Ju
- InterView
- ‘Improve new drug access to treat rheumatoid arthritis'
- by Son, Hyung Min Nov 21, 2024 05:46am
- “Rheumatoid arthritis is not just a painful disease, but a disease that can cause direct damage to the joints. Patients need to start treatment with good treatments in a timely manner, but their access to new drugs is still limited. Switching between JAK inhibitors should be allowed freely so patients can receive personalized treatment.”
